Trial design and rationale of TY-51924 as a novel Na+/H+ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention  by Ishihara, Masaharu et al.
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Background:  Reperfusion  therapy  limits  infarct  size  and improves  survival  in patients  with  ST-elevation
myocardial  infarction  (STEMI).  However,  reperfusion  itself  may,  in  some  cases,  deteriorate  myocardial
damage,  causing  the  so-called  ischemia-reperfusion  injury.  Activation  of  the  Na+/H+ exchanger  (NHE)
at  the  time  of reperfusion  plays  an important  role  in  ischemia-reperfusion  injury.  We  designed  a  Phase
IIa  proof  of  concept  clinical  trial  to evaluate  the potential  of  TY-51924,  an NHE  inhibitor,  as  adjunctive
therapy  to primary  percutaneous  coronary  intervention  (pPCI)  for patients  with  STEMI.
Methods: This is a multicenter,  randomized,  double-blind,  placebo-controlled  clinical  trial  designed  to
evaluate  the efﬁcacy  and  the  safety  of  TY-51924  in  patients  with  ﬁrst  anterior  STEMI  who  are  undergoing
pPCI.  Immediately  before  pPCI,  a bolus  intravenous  injection  followed  by  infusion  of TY-51924 (up  to
30  mg/kg)  or  placebo  was  administered.  Primary  endpoints  were  myocardial  salvage  index  (MSI) deter-
mined  by 201Tl/123I-beta-methyl-p-iodophenyl  pentadecanoic  acid  (BMIPP)  dual-isotope  single photon
emission  computed  tomography  (SPECT)  performed  3–5 days  after  pPCI,  and  safety  up to 7 days.  Sec-
ondary  endpoints  were  the  degree  of  myocardial  injury  based  on  cardiac  enzyme  release  and  QRS  score by
electrocardiogram  (ECG),  cardiac  functions  determined  by  SPECT  or magnetic  resonance  imaging  (MRI),
and  safety  up  to  3 months  following  pPCI.  Furthermore,  MRI  studies  were  also  performed  where possible
3–7  days  and  3 months  after  pPCI.
Discussion: The  appropriateness  of  assessing  safety  and  efﬁcacy  of  TY-51924  as  adjunctive  therapy  to
EMI  w
3  JappPCI  for  patients  with  ST
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ntroduction
It has been well demonstrated that reperfusion therapy limits
nfarct size, and improves left ventricular function and survival in
atients with ST-elevation myocardial infarction (STEMI). Percuta-
eous coronary intervention (PCI) is currently the recommended
hoice of treatment for STEMI, if timely treatment is applicable.
lthough the 30-day mortality of patients with STEMI improved
arkedly, long-term survival did not. The Framingham Heart study
eported an increase in the incidence of heart failure in recent
ecades that paralleled the decrease in mortality after myocardial
∗ Corresponding author. Tel.: +81 6 6833 5012; fax: +81 6 6833 9865.
E-mail address: ishifami@fb3.so-net.ne.jp (M. Ishihara).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.06.006ill be  discussed  in this  study  plan.
anese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
infarction (MI) [1]. Post-MI medications have been demonstrated
to improve ventricular remodeling and function in animal experi-
ments [2,3]. Furthermore, the ﬁnal extent of myocardial cell death
is determined by both ischemic injury and ischemia-reperfusion
injury [4]. Since the introduction of reperfusion therapy for the
reduction of ischemic injury, extensive effort has been invested in
ﬁnding a cardioprotective agent that renders myocardial cells more
resistant to ischemia-reperfusion injury [5–8].
The Na+/H+ exchanger (NHE) is considered to be one of
the pathogenic mechanisms of myocardial ischemia-reperfusion
injury. In ischemic myocardium, NHE is activated by reperfusion
resulting in the inﬂux of Na+ [9]. Increases in intracellular Na+ corre-
late with increases in intracellular Ca2+ via a reverse mode Na+/Ca2+
exchanger (r-NCX), and intracellular Ca2+ overload ultimately leads
to unfavorable myocardial damage [10]. EMD-96785 and cariporide
vier Ltd. All rights reserved.
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Table 1
Inclusion and exclusion criteria.
Inclusion criteria
•  Age: 20–79 years
•  Admission within 6 h of the onset of symptoms
•  Chest pain lasting for ≥30 min
• ST elevation of ≥0.2 mV in 2 or more leads (V1–V4) on standard 12-lead
electrocardiogram
• Thrombolysis in myocardial infarction ﬂow grade 0/1 in LAD on
diagnostic coronary angiography
•  Written informed consent
Exclusion  criteria
•  Prior documented old myocardial infarction or clinical history of deﬁnite
myocardial infarction
•  LMT  stenosis >50%
•  Total occlusion of LCX or RCA
• Left bundle-branch block
•  Suspected acute aortic dissection
• Cardiac arrest or cardiogenic shock
• Thrombolytic therapy or coronary artery bypass graft
•  Hepatic or renal dysfunction (serum total bilirubin ≥3.0 mg/dL, serum
creatinine ≥2.0 mg/dL based on the grade classiﬁcation issued by
Ministry of Health and Welfare, Japan)
• History of allergy or drug hypersensitivity
• Pregnant or breastfeeding women, or women of childbearing potential
• Participation in a clinical trial and administration of the study drug
within 4 months before informed consent
• Past participation in a clinical trial of TY-51924 and administration of the
study drug
•  Patients determined to be ineligible for the trial by the principal
investigator  or subinvestigator for other reasonsM. Ishihara et al. / Journal
nown as NHE inhibitors, were expected to have a clinical beneﬁt.
owever, EMD-96785 administered intravenously at a single high
ose caused vacuolization of the gray matter in rat central ner-
ous systems [11] and the EXPEDITION study of cariporide showed
ncreased cerebrovascular events and perioperative confusion in
atients undergoing coronary artery bypass grafting (CABG) [12].
herefore, a novel strategy is needed for the development of a NHE
nhibitor with a lower risk of central neurotoxicity.
On the basis of a working hypothesis that central neurotoxic-
ty may  be reduced by increasing the water solubility, TY-51924
as designed as a novel NHE inhibitor by introducing a water-
oluble functional group to TY-12533 which was reported to
ave cardioprotective effects against ischemia-reperfusion injury
y NHE inhibition in rats [7]. Intravenous administration of TY-
1924 showed very low distribution to central nervous tissue and
apid elimination from blood and tissues in animal experiments.
n a canine model of ischemia-reperfusion, TY-51924 administered
ntravenously prior to reperfusion reduced MI  size (data not pub-
ished). Furthermore, side effects of TY-51924 requiring therapeutic
are were not seen in a Phase I clinical trial at 0.1–40 mg/kg and in
 Phase IIa pilot trial at 10–30 mg/kg (data not published). There-
ore, to evaluate the efﬁcacy and safety of TY-51924 at 30 mg/kg,
e have designed a protocol for a Phase IIa proof of concept (POC)
rial in patients with ﬁrst anterior STEMI undergoing primary PCI
pPCI).
ethods
verview
This is a multicenter, randomized, double-blind, placebo-
ontrolled clinical trial in Japan. The planned sample size is 100
atients consisting of 50 patients each in the TY-51924 and placebo
roups. The trial is to be approved by the Institutional Review Board
t each institution prior to patient enrollment.
The trial is to be conducted in accordance with the ethical prin-
iples that have their origin in the Declaration of Helsinki and Good
linical Practice (GCP). The Investigational New Drug Application
as submitted to the Pharmaceutical and Medical Devices Agency,
apan, in October 2011, and the summary was registered at the Japic
TI database as Japic CTI-121747 (http://www.japic.or.jp/).
tudy population
Eligible participants will be Japanese patients with ﬁrst anterior
TEMI admitted to the institution within 6 h of the onset of symp-
oms and who will undergo pPCI. Only patients with Thrombolysis
n Myocardial Infarction (TIMI) ﬂow grade 0/1 in the left anterior
escending (LAD) artery conﬁrmed by coronary angiography (CAG)
re to be included. These patients are considered to be appropriate
or precise evaluation of the drug in STEMI [13]. Details of inclu-
ion and exclusion criteria are listed in Table 1. All patients are to
rovide written informed consent prior to enrollment.
rotocol
A detailed trial schedule of assessments is shown in Table 2.
atients who are likely to meet eligibility criteria will be randomly
llocated to the TY-51924 or placebo group in a 1:1 ratio by the
nline trial management system with time from onset to admis-
ion as a dynamic assignment. Study drug packages will consist of
ither TY-51924 containing 1000 mg  or placebo in a blinded man-
er, and the package will be selected according to a drug number
nstructed by the online trial management system. The study drug
ill be administered as follows:LAD, left anterior descending artery; LCX, left circumﬂex artery; LMT, left main
trunk;  RCA, right coronary artery.
• After  ﬁnal eligibility is conﬁrmed by CAG, a bolus intravenous
injection of TY-51924 10 mL (6 mg/kg) or placebo 10 mL  will be
initiated  as a loading dose before crossing the culprit lesion with
a  guide-wire.
• Immediately after the bolus injection, a continuous intravenous
infusion of TY-51924 40 mL/h (24 mg/kg/h) or placebo 40 mL/h
will  be initiated.
• The  infusion can be stopped over 10 min  after the completion
of  pPCI including post-dilation or when the infusion reaches the
total  amount of prepared solution.
It  is prohibited to administer carperitide or nicorandil intra-
venously for concomitant use from obtaining informed consent
through single photon emission computed tomography (SPECT)
study scheduled 3–5 days after pPCI. Antithrombotic agents such as
heparin and antiplatelet agents are likely to be used as concomitant
drugs, any medication other than what described above or devices
could be selected at the discretion of physicians at each institu-
tion. In addition, glycoprotein IIb/IIIa inhibitors are not available
for medication in Japan.
Core  laboratory evaluation
Evaluations  of CAG, SPECT, magnetic resonance imaging (MRI),
and 12-lead electrocardiogram (ECG) are to be performed at each
core laboratory. The data that are acquired and anonymized in each
institution will then be submitted to the core laboratory.
CAG
CAG will be performed just before pPCI to conﬁrm eligibility and
just completion of pPCI to collect the following data:• American  Heart Association (AHA) classiﬁcation and Coronary
Artery  Surgery Study (CASS) classiﬁcation
• TIMI  ﬂow grade
84 M. Ishihara et al. / Journal of Cardiology 63 (2014) 82–87
Table  2
Schedule of assessments.
Study procedures
 Entering 
CCU
3
h
6
h
9
h
12
h
24
h
3D 4D 5D
7D
*1
4W
*1
3M
*1Admissi on
Confir-
mation  of
TIMI 0/1
Before
guidewire
crossing
Initial  TIMI 
2/3
Final
Confir-
mation of
CAG
Comple-
tion of
administ-
ration
Leaving 
cath lab
Informed consent /  patient 
characteristics
°
Consulta tion ° ° ° ° ° °
Chest  pain ° °
12-Lead ECG ° °
*2
 ° ° ° ° °
ECG monitor ing
Body temperature and 
respiratory rate 
° ° °
Blood pres sure and heart rate ° °
*3
 ° ° ° ° °
Laborat ory test ° ° ° ° °
Cardiac enzym e
*4
° ° ° ° ° ° ° °
CAG ° °
Study drug administration
201
Tl/
123
I-BMIPP 
dual- isotope SPECT
99m
Tc-SPECT °
MRI °
Adverse event follow-up
CAG, coronary angiography; CCU, coronary care unit; ECG, electrocardiogram; MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography;
TIMI, thrombolysis in myocardial infarction; 201Tl/123I-BMIPP, 201Tl/123I-beta-methyl-p-iodophenyl pentadecanoic acid.
*1:  7D means day 7 or the day of discharge if the patient is discharged from the hospital before day 7. 4 W means weeks 4 to 6. 3 M means days 90 to 120. *2: If ST re-elevation
is observed within 2 min  after the achievement of the initial TIMI 2/3, ECG is recorded. If ST re-elevation is not observed, ECG is recorded 2 min later. *3: The recording is
performed every 10 min  from 10 min  after the start of study treatment to the completion of treatment. *4: Blood samples for cardiac enzyme measurements are drawn at
t spectively.
•
•
•
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Table 3
Quantitative parameters calculated in SPECT or MRI  study.
SPECT study
Acute  phase on 3–5 days after pPCI
• Infarct size (%): TPD on 201Tl polar-map
• Area at risk (%): TPD on 123I-BMIPP polar-map
• MSI: (area at risk – infarct size)/area at risk
• LV volume (mL) and function (%): LVESV, LVEDV, and LVEF based on
201Tl-QGS data
Follow-up at 3 months after pPCI
• Infarct size (%): TPD on 99mTc-tetrofosmin polar-map
•  LV volume (mL) and function (%): based on 99mTc-tetrofosmin QGS data
MRI  study
Acute phase on 3–7 days after pPCI
• Infarct size 1 (%): volume infarct/volume LV mass for all slices
•  Infarct size 2 (%): volume infarct/volume LV mass for the 4 slices at
identical locations to BBT2WI
•  Area at risk (%): volume edema/volume LV mass for the 4 slices
•  MSI: (area at risk – infarct size 2)/area at risk
• Presence of infarct and transmurality based on the AHA 17 segment
model: 0 = no scar, 1 = 1–25%; 2 = 26–50%; 3 = 51–75%; 4 = >75%
• LV volume (ml) and function (%): LVESV, LVEDV, and LVEF
•  LV wall thickening (%) based on the AHA 17 segment model
Follow-up  at 3 months after pPCI
• Infarct size (%)
•  Presence of infarct and transmurality
• LV volume (mL) and function (%)
• LV wall thickening (%)
AHA, American Heart Association; BBT2WI, black blood T2-weighted images; BMIPP,
beta-methyl-p-iodophenyl pentadecanoic acid; LV, left ventricular; LVESV, left ven-
tricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVEF, lefthe  indicated times after drug administration, in which 3 or 4D mean 48 or 72 h, re
Rentrop  grade
Corrected TIMI frame count
Myocardial  blush grade
PECT
PECT studies
SPECT studies are to be performed 3–5 days after pPCI as the
cute phase, and 3 months after pPCI as follow-up in accordance
ith the protocol of each institution and as instructed by the core
aboratory.
In 201Tl/123I-beta-methyl-p-iodophenyl pentadecanoic acid
BMIPP) dual-isotope SPECT, dual imaging is simultaneously initi-
ted 5 min  after intravenous injection of 111 MBq  of 201Tl [Thallium
201Tl) chloride Injectable NMP; Nihon Medi-Physics, Osaka, Japan]
nd 111 MBq  of 123I-BMIPP (Cardiodine Injectable 123I-BMIPP;
ihon Medi-Physics).
Imaging of 99mTc will be initiated 30–60 min  after intravenous
njection of 740 MBq  of 99mTc-tetrofosmin (Myoview Injectable
yringe; Nihon Medi-Physics).
PECT  analyses
The  area at risk and infarct size will be calculated as the total
erfusion deﬁcit (TPD) [14] using quantitative perfused SPECT
QPS) software (Cedars-Sinai Medical Center, Los Angeles, CA, USA)
n reference to the published database of the normal values for
yocardial SPECT [15]. With quantitative gated SPECT (QGS) data,
he left ventricular (LV) function and volume will be calculated
sing QGS software (Cedars-Sinai Medical Center). The data to be
ollected are listed in Table 3 (upper).
ventricular ejection fraction; MRI, magnetic resonance imaging; MSI, myocardial
salvage  index; pPCI, primary percutaneous coronary intervention; QGS, quantita-
tive  gated SPECT; SPECT, single photon emission computed tomography; TPD, total
perfusion deﬁcit.
 of Cardiology 63 (2014) 82–87 85
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Table 4
Other observations and examinations for efﬁcacy and safety evaluation.
Other observations and examinations for efﬁcacy
•  Cardiac enzymes: CK, CK-MB and TnT (peak value and AUC  between
before pPCI and 72 h after drug administration)
•  Chest pains evaluated by NRS: before pPCI and at initial TIMI 2/3
acquired by pPCI
•  Ventricular arrhythmia until leaving cath lab: AIVR, NSVT/SVT, and Vf/VF
• Events up to 3 months after pPCI: death (cardiac death, non-cardiac
death,  or death from unknown causes), re-admission due to heart failure,
re-infarction, implementation of revascularization, and stroke (cerebral
infarction, cerebral hemorrhage, and stroke not otherwise speciﬁed)
Observations and examinations for safety evaluation
•  Subjective and objective symptoms, 12-lead ECG, continuous ECG
monitoring, body temperature, respiratory rate, blood pressure, heart
rate, and laboratory test ﬁndings
• Adverse events and side effects occurred during the 3 months after pPCI
CK, creatine kinase; TnT, troponin T; AUC, area under the curve of concen-
tration  versus time; NRS, numerical rating scale; pPCI, primary percutaneous
coronary  intervention; TIMI, thrombolysis in myocardial infarction; AIVR, accel-
The  sample size was  calculated using MSI 3–5 days after pPCI
determined by SPECT in the pilot trial. As the trial showed that MSI
for TY-51924 at doses of 10, 20, and 30 mg/kg were 0.118 ± 0.167,
Table 5
Study endpoints.
Primary end points
Efﬁcacy:  MSI  by SPECT on 3–5 days after pPCI
Safety: the incidence of adverse events and side effects up to 7 days after
pPCI
Secondary endpoints
Efﬁcacy
•  Acute phase imaging by SPECT on 3–5 days or by MRI  on 3–7 days after
pPCI
Infarct size, ventricular volume (LVESV and LVEDV), and function (LVEF)
by SPECT and MRI
MSI,  LV wall thickening, and transmural extent by MRI
•  Follow-up imaging by SPECT or MRI at 3 months after pPCI
Infarct  size, LVESV, LVEDV, and LVEF by SPECT and MRI
MSI  by SPECT and MRI (calculated using data on area at risk in the acute
phase)
LV wall thickening by MRI
•  Infarct size by serum CK, CK-MB, and TnT release (peak and AUC)
between before pPCI and 72 h after drug administration
•  Myocardial damage evaluated by QRS score at the time of conﬁrmation
of  TIMI 0/1 on diagnostic CAG, leaving the catheter room (or entering
CCU) on 2, 7 days, and 4 weeks
• Status of ST re-elevation, chest pain, and ventricular arrhythmia during
pPCI
• ST resolution at the time of leaving the catheter room or entering CCU
• Events up to 3 months and those in Table 4 described in other
observations  and examinations for efﬁcacy evaluation
Safety
•  The incidence of adverse events and side effects up to 3 months after pPCI
MSI, myocardial salvage index; SPECT, single photon emission computed tomo-
graphy; MRI, magnetic resonance imaging; pPCI, primary percutaneous coronaryM. Ishihara et al. / Journal
RI
RI  studies
MRI  studies are to be performed where possible 3–7 days after
PCI as the acute phase, and 3 months after pPCI as follow-up
sing 1.5 or 3.0T scanners and dedicated cardiac coils (various
endors). All images are to be acquired during shallow inspira-
ion and electrocardiographic triggering. The studies include cine,
lack blood T2-weighted images (BBT2WI), myocardial perfusion,
nd late gadolinium enhancement (LGE) at acute phase and cine,
nd LGE for a follow-up scan.
Cine images are to be acquired in 3 long-axis orientations (verti-
al, horizontal, and 4-chamber views) and in contiguous short-axis
rientation covering the entire left ventricle using a steady state
ree precession (SSFP) sequence with temporal resolution of less
han 60 ms  between phases. BBT2WIs are to be acquired in 2
ong-axis orientations (vertical and horizontal) and in short-axis
rientation with 4 slices equally distributed from base to apex
sing short-tau inversion recovery (STIR) sequence with double
nversion pre-pulse. Myocardial perfusion MRI  images are to be
cquired in the resting state in identical locations as BBT2WI. For
yocardial perfusion imaging, 0.05 mmol/kg of gadolinium (Gd)
ontrast medium is to be injected at a ﬂow rate of 4 mL/s followed
y 15–20 mL  of saline at the same ﬂow rate. There will be 90◦ satura-
ion pre-pulse and ﬁxed pre-pulse delays used. Inversion recovery
radient echo imaging will be applied in combination with Gd at a
umulative dose of 0.15 mmol/kg. After determination of the inver-
ion time nulling the normal myocardium, LGE images are to be
btained 5–10 min  after Gd administration in identical locations as
ine images.
RI  analyses
MRI  analyses are to be performed using dedicated cardiac anal-
sis software (CMR42; Circle Cardiovascular Imaging Inc., Calgary,
lberta, Canada). A myocardial region is regarded as affected if
t least 10 adjacent myocardial pixels reveal a signal intensity of
reater than 2 standard deviations (SD) of remote myocardium for
dema and greater than 5 SD in LGE images [16,17]. The data listed
n Table 3 (lower) are collected as described previously [18,19].
2-Lead  ECG
According to the schedule of assessments (Table 2), 12-lead
CGs are to be recorded at a paper speed of 25 mm/s and an ampliﬁ-
ation of 10 mm/mV.  Analyses of ST segment deviation and Q waves
re to be performed and QRS scores calculated using the Selvester
RS scoring system [20].
ther  observations and examinations for efﬁcacy and safety
valuation
Parameters listed in Table 4 are to be assessed in accordance
ith the schedule of assessments (Table 2). Then chest pains are to
e evaluated using a numerical rating scale [21] and re-admission
ue to heart failure is diagnosed using the Framingham criteria [22].
ndpoints
Endpoints in this trial are listed in Table 5.
rimary endpoints
The  primary efﬁcacy endpoint is myocardial salvage index (MSI)
easured by SPECT 3–5 days after pPCI. The primary safety end-
oint is the incidence of adverse events and side effects up to 7 days
fter pPCI.erated idioventricular rhythm; NSVT, nonsustained ventricular tachycardia; SVT,
sustained ventricular tachycardia; Vf, ventricular ﬁbrillation; VF, ventricular ﬂutter;
ECG, electrocardiogram.
Secondary endpoints
The  secondary efﬁcacy endpoints are SPECT, MRI  ﬁndings, car-
diac enzymes, and 12-lead ECG evaluations. The secondary safety
endpoint is the incidence of adverse events and side effects up to 3
months after pPCI.
Sample  sizeintervention; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; LV, left ventricular; CK,
creatine kinase; TnT, troponin T; AUC, area under the curve of concentration versus
time; TIMI, thrombolysis in myocardial infarction; CAG, coronary angiography; CCU,
coronary care unit.
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.335 ± 0.010, and 0.192 ± 0.184 (mean ± SD), respectively, the
ean MSI  of placebo and the active drug were assumed to be 0.1
nd 0.2, respectively, and the common SD was estimated as 0.168.
he number of subjects in whom a 0.1 improvement with the active
rug is detectable with a power of 80% at a two-sided 0.05 signif-
cance level is 46 per group. Assuming a dropout rate of 10%, the
otal ﬁnal sample size is determined to be 100 patients.
tatistical analysis
All  the subjects treated with the study drug are to be included
n the safety population, excluding subjects with GCP violations. In
ddition, the efﬁcacy population is to be based on the per-protocol
et. The test is to be at a two-sided 0.05 signiﬁcance level, unless
therwise noted. If the interval estimation is to be made, the con-
dence coefﬁcient is to be set at 95%.
Categorical variables are to be summarized as the number of
ubjects and the percentage, and the inter-group comparison is to
e conducted using the Wilcoxon rank-sum test or Fisher’s exact
est. Continuous variables are to be summarized as the mean, SD,
edian, and interquartile range (IQR), and the inter-group compar-
son is to be conducted using the unpaired Student’s t-test.
As  the primary endpoint for efﬁcacy, the MSI  at the acute phase
valuated by SPECT is to be summarized as the mean, SD, max-
mum value, minimum value, median, IQR, and 95% conﬁdential
nterval per group. Inter-group comparison is to be conducted using
he unpaired Student’s t-test, but the statistical test method may
hange if another test method is considered to be more appropriate
ased on the results of the blinded review.
Exploratory analyses are also to be performed for MSI, infarct
ize, and so on by SPECT at the acute phase using a linear ﬁxed effect
odel with treatment group, duration from onset to admission,
nd the factors selected in the blinded review as covariates. In the
nalysis of time event data, Kaplan–Meier curves are to be provided
nd log-rank tests performed.
As the primary endpoint for safety, the incidence rates of adverse
vents and side effects up to 7 days after pPCI are to be calculated
or each treatment group.
All  statistical analyses are to be performed using SAS software
ersion 9.2 (SAS Institute Japan Ltd., Tokyo, Japan).
ndependent data monitoring committee
An independent data monitoring committee (IDMC) compris-
ng 2 clinical experts and a biostatistical expert independent of
his trial has been established. The IDMC will recommend whether
he trial should continue or discontinue on the basis of safety and
nterim results of futility, which are to be analyzed by an external
iostatistics group independent of the trial.
iscussion
The primary objective of this trial is to evaluate the efﬁcacy
nd safety of an intravenous injection of TY-51924, a novel NHE
nhibitor, as an adjunct to pPCI in patients with ﬁrst anterior STEMI.
t has been well demonstrated that NHE plays an important role in
schemia-reperfusion injury. Experimental studies have reported
hat its inhibition may  reduce infarct size.
Three large-scale clinical trials of NHE inhibitors have been
eported, but each of them failed to demonstrate the beneﬁts of
HE inhibitors. In GUARDIAN, cariporide was given to patients
ith unstable angina (UA)/non-STEMI, or who were undergoing
igh-risk PCI or being subjected to high-risk coronary artery bypass
rafting (CABG) [23]. But beneﬁt was limited to CABG in which
ariporide was administered prior to ischemia. However, EXPEDI-
ION in patients undergoing CABG reported that higher dose ofdiology 63 (2014) 82–87
cariporide  administered before surgery had reduced the incidence
of MI  events, but increased the incidence of cerebrovascular and
neuronal events [12]. In ESCAMI, eniporide was administered just
before reperfusion in patients with STEMI, but did not signiﬁcantly
reduce cardiac enzyme release at any doses [24]. One possible rea-
son for its failure is under-titration to avoid the neuronal side effects
[25,26]. Therefore, developing NHE inhibitors without side effects,
particularly without central neurotoxicity appeared to be an impor-
tant matter.
TY-51924 is a hydrophilic compound. In a Phase I double-
blind, placebo-controlled trial, 88 healthy male subjects received
an intravenous infusion of saline or TY-51924 at 0.1–40 mg/kg. Sub-
sequently, a Phase IIa pilot trial, multicenter, open clinical trial was
designed in 18 patients with ﬁrst anterior STEMI undergoing pPCI.
Immediately before pPCI, a bolus intravenous injection followed
by infusion of TY-51924 (at 10, 20, or 30 mg/kg) was initiated. TY-
51924 has been found to be safe and well tolerated in Phase I
and IIa pilot trials (data not published). Hence, a planned dosage
of TY-51924 in this trial was selected as 30 mg/kg. Furthermore,
in consideration of the principal time-window of NHE activation
after reperfusion and the time required for the pPCI procedure, TY-
51924 is rapidly administered via intravenous route at 6 mg/kg just
prior to pPCI and followed by continuous infusion within 1 h at
24 mg/kg/h. It is considered that sufﬁcient blood concentration of
TY-51924 must be maintained by this dosage and dose regimen. In
addition, as a cause of the cerebrovascular events in EXPEDITION, it
was suggested that prolonged NHE inhibition and an abrupt with-
drawal of drug could lead to platelet hyperactivity as the rebound
phenomenon [12]. The effects of TY-51924 on platelet aggregation
were not observed in the Phase I trial (data not published) and
duration of drug administration in this trial are much shorter than
that in EXPEDITION. Therefore, considering the chemical proﬁles of
TY-51924 and designed protocol, the pharmacological potency of
TY-51924 for infarct size reduction must be exerted safely in this
trial.
The goal of reperfusion therapy is to improve short- and long-
term outcomes of patients with STEMI. The beneﬁts are obtained
by reducing infarct size. In the therapeutic evaluation of various
drugs for reperfusion injury, cardiac enzyme released in peripheral
blood is used as a surrogate biomarker for infarct size. However,
infarct size largely depends on the risk area, and the salvage index
is a preferable measure to evaluate the cardioprotective effect of
treatment [27]. Therefore, we will use MSI  assessed by Tl/BMIPP
SPECT as the primary efﬁcacy endpoint in this study. BMIPP SPECT
reﬂects fatty acid metabolism and a deﬁcit of BMIPP accumulation
at 1–2 weeks after STEMI is well correlated to the risk area [28],
whereas a deﬁcit of Tl accumulation represents an area of infarc-
tion. In addition to the cardiac enzymes and QRS score, an MRI  study
as an exploratory assessment is to be performed, as well as a SPECT
study to support evaluation of TY-51924.
Based on the above discussion, this trial is expected to clar-
ify the clinical value of TY-51924 compared to placebo in patients
with STEMI by assessing safety and the signiﬁcance of infarct size
reduction.
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